undamentalytics Newsletter
Sign in

Neogenomics Inc (NEO) stock

Add to watchlist

Add holding +

NASDAQ: NEO Nasdaq Life Sciences Tools & Services Next results ~January 11, 2027

C Fundamentals grade

Neogenomics Inc is a US-listed company in the life sciences tools & services industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$6.2

Valuation models combined (3)

Base case. Range ~$5.5–$7.4. Weighted average of 3 models (growth cash-flow model, forward price-to-earnings vs peers, revenue-to-maturity model), the growth cash-flow model counting double.

Price vs value

No Buy/Hold/Sell rating is issued: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Neogenomics Inc valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

Value diary

Our note on each quarter Neogenomics files

Where Neogenomics stands after its latest 10-Q

Revenue for the twelve months to September 2026 was $788m, up 11.1% on a year earlier, about the same pace as a quarter earlier. Free-cash-flow margin fell to -3.6% from -2.4% a year earlier. Operating margin widened to -6.3% from -17.0%. Against its peers on growth, profitability, cash generation and balance sheet, it grades C. It passes 2 of our 7 financial-health checks. Our revenue-to-maturity cash-flow model value is $6.32 a share, against a share price of $17.25.

Source: 10-Q filed October 28, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~January 11, 2027 (estimated)

Neogenomics Inc's trailing-twelve-month revenue grew 11.1% year on year, with a free-cash-flow margin of -3.6%. Where it lags: days sales outstanding of 99 days ranks 44 of 48 life sciences tools & services companies we cover.

Current signal Free cash flow diverging from earnings: TTM free cash flow fell 67.7% while net income grew 71.5%: a 139pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Margins widening. Operating margin is up 10.8 points on a year ago.
  • Beating expectations. Earnings per share beat the analysts' consensus estimate in each of the last four quarters.

Things to watch

  • Loss-making. Operating margin is -6.3%: costs exceed revenue.
  • Burning cash. Free cash flow was -3.6% of revenue over the last 12 months.
  • Volatile shares. Over the past year the shares showed annualised volatility of 53% and a beta of 1.1 against the S&P 500.
  • Below peers: days sales outstanding. Days sales outstanding of 99 days ranks 44 of 48 life sciences tools & services companies we cover (median 62 days).
  • Heavily shorted. 13.0% of the shares available to trade are sold short (5.8 days of average volume to cover).

Latest results: FY2026 Q3

Filed October 28, 2026
Earnings per share
$0.07 against an average estimate of $0.06: beat by 26.2%
Revenue
$209m, up 11.4% on a year earlier
Share reaction
+3.8% in the first session after the results on October 28, 2026, against 0.0% for the S&P 500
Next report
October 28, 2026; average EPS estimate $0.07

Neogenomics' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+3.2%
  • 1 week-1.4%
  • 1 month-7.9%
  • This year+40.2%
  • 1 year+74.0%
  • 5 years-55.6%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$788M
Operating margin
-6.3%
Net margin
-4.1%
EPS (TTM, diluted)
$-0.25

Growth

Revenue growth
+11.1%
Change in growth rate
−0.1 pts
Share count change
+1.2%

Cash

Free cash flow (TTM)
-$28.6M
FCF margin
-3.6%
Stock pay % of revenue
4.4%

Earnings

Last results
October 28, 2026
Next results (est.)
January 11, 2027

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results
  2. Results
  3. Leadership
  4. Results
  5. Announcement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Neogenomics Inc valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Valuation models

We value Neogenomics Inc as an operating company, with every model that fits that kind of business. Cost of equity 9.9%: the 10-year Treasury yield (4.9%) plus a beta of 1.1 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$5.5 ~$3.0–$7.2 Primary model, counts double
Forward price-to-earnings vs peers Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$7.4 ~$5.9–$9.6 Included
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$21 ~$17–$49 Left out: far from the other models (more than 3x away from their median)
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. ~$6.3 ~$4.5–$8.5 Included
Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$6.2 ~$5.5–$7.4 3 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Neogenomics Inc with Life Sciences Tools & Services in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 2016201720182019202020212022202320242025Now
Share price$8.57$8.86$12.61$29.25$53.84$34.12$9.24$16.18$16.48$11.76$16.49
Market value$665m$704m$1.2bn$3.0bn$6.0bn$4.1bn$1.1bn$2.0bn$2.1bn$1.5bn$2.1bn
+ Net debt (− = net cash)$97m$95m$104m−$68m−$57m$217m$272m$196m$179m$185m$235m
Enterprise value$761m$799m$1.3bn$3.0bn$6.0bn$4.3bn$1.4bn$2.2bn$2.3bn$1.7bn$2.4bn
Multiples
Price / sales 2.9x2.9x4.2x7.4x13.5x8.5x2.3x3.4x3.2x2.1x2.7x
Price / earnings ——n/mn/mn/m——————
Price / free cash flow 47.7x161.9x37.9xn/m———————
EV / EBITDA 42.1x43.2x48.7x88.8xn/m——————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

34 /100

Weak moat

How hard Neogenomics's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Cash operating profit has been a median -3.6% of total assets over 10 years.

  • Pricing power 14 / 20

    Gross margin has been a median 43.5%, moving by 3.4 percentage points (standard deviation) across 9 years.

  • Durability 10 / 20

    Operating margin has been a median -14.3%; its worst year was -34.8%.

  • Cash conversion 2 / 20

    Free cash flow was positive in 2 of 9 years, at a median -3.6% of revenue.

  • Discipline 13 / 20

    The diluted share count rose 6.5% over five years; stock-based pay has been a median 3.1% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (39 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $0.20 +70% $808m +11%
Next $0.33 +60% $886m +10%

Next year's EPS estimate has moved −3.5% in 90 days, across 11 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +11.6% on 90 days ago. In the last 30 days, 3 analysts raised Neogenomics Inc's forecast and 0 cut it.

Consensus EPS forecast Neogenomics Inc, last 90 days
$0.15 $0.20 $0.25 $0.30 $0.35 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: $0.18 Current fiscal year, 60 days ago: $0.18 Current fiscal year, 30 days ago: $0.18 Current fiscal year, 7 days ago: $0.19 Current fiscal year, Now: $0.20 $0.20 Next fiscal year, 90 days ago: $0.34 Next fiscal year, 60 days ago: $0.34 Next fiscal year, 30 days ago: $0.34 Next fiscal year, 7 days ago: $0.34 Next fiscal year, Now: $0.33 $0.33

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago $0.18$0.34
60 days ago $0.18$0.34
30 days ago $0.18$0.34
7 days ago $0.19$0.34
Now $0.20$0.33

Earnings against estimates

Quarter toEstimateActualSurprise
Sept 2026 $0.06 $0.07 +26.2%
Jun 2026 $0.03 $0.05 +48.6%
Mar 2026 $0.00 $0.01 +800.9%
Dec 2025 $0.04 $0.06 +50.0%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

11 analysts, Oct 2026
Buy873%
Hold327%
Sell00%

Monthly trend

  1. Oct 202626311
  2. Sep 202626412
  3. Aug 202626412
  4. Jul 202626412

Counts of recommendations published by analysts covering Neogenomics Inc, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
13.0%
of tradable shares
Days to cover
5.78
at average volume
Short interest, 1 month
−15%
to October 15, 2026
Held by institutions
—
of shares
Held by insiders
2.1%
of shares
Employees
2,500
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months +68.8%

$9.77 on October 31, 2025 to $16.49

ThenNowEffect
Revenue (last 12 months) $689m $766m +11.2%
P/S multiple 1.8x 2.8x +54.1%
Share count 127m 129m −1.5%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

Last 3 years +8.0%

$15.27 on November 3, 2023 to $16.49

ThenNowEffect
Revenue (last 12 months) $552m $766m +38.9%
P/S multiple 3.5x 2.8x −19.5%
Share count 125m 129m −3.4%

Biggest factor: revenue. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
NEO−37%−73%+75%+2%−29%+40%
Industry peers (median)+5%−51%−3%−15%−2%+15%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
NEO33%17%58%42%42%64%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
NEO−49%−82%−41%−27%−74%−46%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 92% from February 12, 2021 to July 31, 2025. Getting back needed a 1137% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$7.19 – $19.91
From 52-week high
−17.2%
vs 50-day average
−6.7%
vs 200-day average
+28.8%
Volatility (1 year)
53%
Beta vs S&P 500
1.08

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
6 up, 6 down
typical move ±11.8%
After a week
4 up, 7 down
typical move ±13.1%
After a month
6 up, 4 down
typical move ±21.1%
Results releasedNext dayS&P 500 next day5 days21 days
October 28, 2026 +3.8% 0.0% — —
October 5, 2026 −10.6% +1.2% −12.3% —
July 28, 2026 +16.2% −1.3% +24.0% +32.2%
April 28, 2026 +4.1% −0.5% +2.9% +18.4%
February 17, 2026 −9.8% +0.7% −15.2% −29.6%
January 12, 2026 −1.7% 0.0% −4.0% −13.0%
October 28, 2025 +1.2% +0.3% −0.6% +19.4%
July 29, 2025 −21.1% −0.4% −13.0% +9.6%
April 29, 2025 −35.8% +0.7% −22.9% −26.1%
February 18, 2025 −11.8% +0.5% −24.5% −31.0%
November 5, 2024 +9.3% +3.7% +15.5% +21.6%
July 29, 2024 +16.1% −0.4% +8.9% +10.1%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Neogenomics Inc in five measures

Fundamentals grade C
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Neogenomics Inc
$550M $600M $650M $700M $750M $800M FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Revenue (TTM), FY23 Q4: $591.6M Revenue (TTM), FY24 Q1: $610.7M Revenue (TTM), FY24 Q2: $628.2M Revenue (TTM), FY24 Q3: $644.1M Revenue (TTM), FY24 Q4: $660.6M Revenue (TTM), FY25 Q1: $672.4M Revenue (TTM), FY25 Q2: $689.2M Revenue (TTM), FY25 Q3: $709.2M Revenue (TTM), FY25 Q4: $727.3M Revenue (TTM), FY26 Q1: $746M Revenue (TTM), FY26 Q2: $766.3M Revenue (TTM), FY26 Q3: $787.8M $787.8M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q4 $591.6M
FY24 Q1 $610.7M
FY24 Q2 $628.2M
FY24 Q3 $644.1M
FY24 Q4 $660.6M
FY25 Q1 $672.4M
FY25 Q2 $689.2M
FY25 Q3 $709.2M
FY25 Q4 $727.3M
FY26 Q1 $746M
FY26 Q2 $766.3M
FY26 Q3 $787.8M
Revenue growth, TTM YoY Neogenomics Inc
8% 10% 12% 14% 16% 18% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Revenue growth, TTM YoY, FY23 Q4: 16.1% Revenue growth, TTM YoY, FY24 Q1: 15.3% Revenue growth, TTM YoY, FY24 Q2: 13.9% Revenue growth, TTM YoY, FY24 Q3: 12.1% Revenue growth, TTM YoY, FY24 Q4: 11.6% Revenue growth, TTM YoY, FY25 Q1: 10.1% Revenue growth, TTM YoY, FY25 Q2: 9.7% Revenue growth, TTM YoY, FY25 Q3: 10.1% Revenue growth, TTM YoY, FY25 Q4: 10.1% Revenue growth, TTM YoY, FY26 Q1: 10.9% Revenue growth, TTM YoY, FY26 Q2: 11.2% Revenue growth, TTM YoY, FY26 Q3: 11.1% 11.1%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q4 16.1%
FY24 Q1 15.3%
FY24 Q2 13.9%
FY24 Q3 12.1%
FY24 Q4 11.6%
FY25 Q1 10.1%
FY25 Q2 9.7%
FY25 Q3 10.1%
FY25 Q4 10.1%
FY26 Q1 10.9%
FY26 Q2 11.2%
FY26 Q3 11.1%
Operating margin (TTM) Neogenomics Inc
-20% -15% -10% -5% 0% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Operating margin (TTM), FY23 Q4: -18.2% Operating margin (TTM), FY24 Q1: -16.9% Operating margin (TTM), FY24 Q2: -15.2% Operating margin (TTM), FY24 Q3: -14.3% Operating margin (TTM), FY24 Q4: -13.9% Operating margin (TTM), FY25 Q1: -13.3% Operating margin (TTM), FY25 Q2: -16.7% Operating margin (TTM), FY25 Q3: -17.0% Operating margin (TTM), FY25 Q4: -15.9% Operating margin (TTM), FY26 Q1: -14.2% Operating margin (TTM), FY26 Q2: -8.9% Operating margin (TTM), FY26 Q3: -6.3% -6.3%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q4 -18.2%
FY24 Q1 -16.9%
FY24 Q2 -15.2%
FY24 Q3 -14.3%
FY24 Q4 -13.9%
FY25 Q1 -13.3%
FY25 Q2 -16.7%
FY25 Q3 -17.0%
FY25 Q4 -15.9%
FY26 Q1 -14.2%
FY26 Q2 -8.9%
FY26 Q3 -6.3%
FCF margin (TTM) Neogenomics Inc
-8% -6% -4% -2% 0% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 FCF margin (TTM), FY23 Q4: -5.2% FCF margin (TTM), FY24 Q1: -6.5% FCF margin (TTM), FY24 Q2: -4.7% FCF margin (TTM), FY24 Q3: -3.3% FCF margin (TTM), FY24 Q4: -5.2% FCF margin (TTM), FY25 Q1: -4.8% FCF margin (TTM), FY25 Q2: -2.8% FCF margin (TTM), FY25 Q3: -2.4% FCF margin (TTM), FY25 Q4: -3.0% FCF margin (TTM), FY26 Q1: -0.7% FCF margin (TTM), FY26 Q2: -1.0% FCF margin (TTM), FY26 Q3: -3.6% -3.6%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q4 -5.2%
FY24 Q1 -6.5%
FY24 Q2 -4.7%
FY24 Q3 -3.3%
FY24 Q4 -5.2%
FY25 Q1 -4.8%
FY25 Q2 -2.8%
FY25 Q3 -2.4%
FY25 Q4 -3.0%
FY26 Q1 -0.7%
FY26 Q2 -1.0%
FY26 Q3 -3.6%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q, 10-Q/A. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Sept 2026
Income
Revenue 232 240 277 409 444 484 510 592 661 727 788
Gross profit 98 102 127 197 186 187 188 245 290 314 353
EBITDA 18 18 26 33 12 −89 −122 −70 −53 −80 −15
Operating income 2 3 10 13 −14 −119 −158 −108 −92 −116 −49
Net income −6 −0 3 8 4 −8 −144 −88 −79 −108 −32
Diluted EPS — — — — — — — — — — −$0.25
Growth (year on year)
Revenue — +3.6% +15.2% +47.7% +8.7% +9.0% +5.2% +16.1% +11.6% +10.1% +11.1%
EBITDA — +2.2% +39.7% +29.1% −64.3% −843.5% — — — — —
Operating income — — — +29.5% −207.6% — — — — — —
Margins
Gross margin 42.3% 42.4% 46.0% 48.1% 41.8% 38.6% 36.9% 41.3% 43.9% 43.2% 44.8%
EBITDA margin 7.8% 7.7% 9.3% 8.2% 2.7% −18.3% −24.0% −11.9% −8.0% −11.0% −1.9%
Operating margin 0.9% 1.2% 3.6% 3.2% −3.1% −24.5% −30.9% −18.2% −13.9% −15.9% −6.3%
Net margin −2.6% −0.2% 1.0% 2.0% 0.9% −1.7% −28.3% −14.9% −11.9% −14.9% −4.1%
Free-cash-flow margin 6.0% 1.8% 11.0% 0.8% −6.2% −18.8% −19.0% −5.2% −5.2% −3.0% −3.6%
Cash flow
Cash from operations 21 18 45 23 1 −27 −66 −2 7 5 4
Capital spending 8 14 14 20 29 64 31 29 41 27 33
Free cash flow 14 4 30 3 −28 −91 −97 −31 −34 −22 −29
Stock-based pay 5 6 7 10 10 22 25 25 33 41 35
Free cash flow after stock pay 9 −2 24 −7 −38 −113 −122 −55 −67 −63 −63
Balance sheet
Cash 13 13 10 173 229 317 263 342 367 160 139
Total debt 109 108 114 105 172 534 535 538 546 345 375
Net debt (negative = net cash) 97 95 104 −68 −57 217 272 196 179 185 235
Diluted shares 78m 79m 92m 104m 112m 120m 124m 126m 127m 128m 129m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 7 checks passed · September 30, 2026
What it owns · $1.4bn
Short-term assets $410mLonger-term assets $967m
What it owes, and who funded it · $1.4bn
Short-term liabilities $116mLonger-term liabilities $460mShareholders' equity $801m
  • Short-term assets cover short-term liabilities $410m of assets due within a year against $116m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $410m short-term assets against $460m of longer-dated liabilities.
  • More cash than debt $139m of cash against $375m of debt.
  • Debt below 40% of shareholders' equity Debt is 47% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 50% to 47% over five years.
  • A year's operating cash flow covers at least 20% of debt $4m of operating cash flow against $375m of debt.
  • Operating profit covers interest at least five times over Operating income of −$49m against $3m of interest.

From Neogenomics Inc's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+1.2%
year over year
R&D spending
5.0%
of revenue
Days sales outstanding
99 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in life sciences tools & services
Last 12 months unless stated NEO RGEN TXG AZTA VCYT TECH Median
Revenue, last 12 months $788m $806m $617m $614m $562m $1.2bn $229m
Revenue growth, last 12 months 11.1% 13.8% −4.3% 4.9% 17.3% −0.4% 6.9%
Revenue growth, 3-year average 11.1% 7.3% 2.8% −0.9% 19.6% 2.2% 2.9%
Revenue growth, latest quarter 11.4% 10.9% −12.6% 12.0% 15.5% 1.3% 8.5%
Gross margin 44.8% 53.5% 70.0% 44.0% 71.7% 65.8% 51.9%
Operating margin −6.3% 2.3% −14.3% −28.6% 18.8% 20.7% −14.3%
Operating margin, 3-year average −12.5% 1.4% −23.3% −15.0% 1.6% 15.6% −22.4%
Net margin −4.1% −1.5% −12.2% −20.0% 20.4% 15.0% −16.1%
Cash from operations / revenue 0.5% 16.1% 20.6% 6.2% 31.7% 24.0% 1.3%
Free-cash-flow margin −3.6% 13.2% 19.7% 1.6% 29.5% 21.7% −2.2%
Free-cash-flow margin, 3-year average −3.1% 16.6% 7.8% 5.0% 19.0% 21.0% 0.6%
Stock pay / revenue 4.4% 4.2% 16.0% 3.1% 8.6% 3.4% 4.4%
Change in share count 1.2% 0.3% 4.2% −1.1% 2.5% −1.7% 1.0%

Median of all 54 companies we cover in life sciences tools & services. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

54 life sciences tools & services companies
Measure Company Peer median Rank
Revenue growth Growth 11.1% 6.9% 20 of 54
Change in growth rate Growth -0.1pp +0.4pp 31 of 54
Gross margin Profitability 44.8% 52.0% 30 of 45
Operating margin Profitability -6.3% -14.3% 22 of 52
Net margin Profitability -4.1% -12.2% 22 of 54
Free-cash-flow margin Cash generation -3.6% -1.3% 29 of 54
Stock pay as % of revenue Cash generation 4.4% 4.4% 27 of 53
Long-term debt as % of assets Balance sheet 27.2% 26.3% 20 of 35
Change in share count Balance sheet 1.2% 1.0% 25 of 46
Days sales outstanding Balance sheet 99 days 62 days 44 of 48

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Client Direct Billing $519M 71.3% ▲ 9.1%
Commercial Insurance $118M 16.2% ▲ 17.7%
Medicare and Other Governmental $90.9M 12.5% ▲ 7.4%
Self Pay Services $114,000 0.0% ▼ 83.3%

From Neogenomics Inc's 10-K filed February 17, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$2.1B
Institutions reporting
264
Shares held vs prior quarter
▲ 8.0%
Positions opened / closed
54 / 42

Top buyers and sellers, Q2 2026: 148 institutions bought and 104 sold ; the biggest buyer was First Trust Advisors LP (+4.0M shares) and the biggest seller D. E. Shaw & Co., Inc (−2.0M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Blackrock, Inc. $304M 20.9M 14.4% ▲ 4.6%
First Light Asset Management, LLC $179M 12.3M 8.5% ▲ 26.2%
First Trust Advisors LP $148M 10.1M 7.0% ▲ 64.1%
Greenhouse Funds LLLP $125M 8.6M 5.9% ▼ 5.8%
Vanguard Portfolio Management LLC $118M 8.1M 5.6% ▲ 5.8%
Vanguard Capital Management LLC $84.1M 5.8M 4.0% ▲ 1.9%
State Street Corp $78.3M 5.4M 3.7% ▲ 4.8%
Nomura Asset Management International Inc. $73.5M 5.0M 3.5% ▲ 45.9%
Braidwell LP $71.8M 4.9M 3.4% ▼ 12.4%
Schroder Investment Management Group $61.9M 4.3M 2.9% ▲ 21.7%
Geode Capital Management, LLC $50M 3.4M 2.4% ▲ 6.1%
Millennium Management LLC $44.9M 3.1M 2.1% ▲ 38.5%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Neogenomics Inc's complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $0 net buying

No open-market insider trades reported in the last 12 months.

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Trades by members of Congress

All 7 trades and filings

In the last 12 months, 1 member of Congress disclosed 1 purchase and 0 sales of Neogenomics Inc shares.

  • Gilbert Ray Cisneros, Jr.(D-CA 31):Purchase, $1,001 - $15,000, traded August 7, 2026, filed September 10, 2026
  • Gilbert Ray Cisneros, Jr.(D-CA 31):Purchase, $1,001 - $15,000, traded May 7, 2025, filed June 6, 2025
  • Dwight Evans(D-PA 3):Sale (full), $1,001 - $15,000, traded March 30, 2022, filed April 25, 2022

Value ranges as filed; reports can arrive up to 45 days after a trade.

Earnings dates and SEC filings

Results announcements

Next expected around January 11, 2027 estimated from the company's past filing pattern, not announced

  • October 28, 2026
  • October 5, 2026
  • July 28, 2026
  • April 28, 2026
  • February 17, 2026
  • January 12, 2026

Recent SEC filings

Data status

When each part of this page on Neogenomics Inc was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Neogenomics Inc in brief

What does Neogenomics Inc do?
Neogenomics Inc is a US-listed company in the life sciences tools & services industry. Its financial year ends in December.
What is Neogenomics Inc's stock ticker?
Neogenomics Inc trades under the ticker NEO on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Neogenomics Inc's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Neogenomics Inc reported revenue of $788M, 11.1% higher than a year earlier, according to its SEC filings.
What is Neogenomics Inc's free cash flow?
Neogenomics Inc's free-cash-flow margin is -3.6% of revenue over the trailing twelve months, ranking 29 of the 54 life sciences tools & services companies we cover.
Who are Neogenomics Inc's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., First Light Asset Management, LLC and First Trust Advisors LP. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Neogenomics Inc's market cap?
On November 2, 2026, Neogenomics Inc's market capitalisation was about $2.1B and net debt of $235M. Market figures come from third-party market data and may be delayed.
How much debt does Neogenomics Inc have?
Neogenomics Inc's debt-to-equity ratio is 46.8%, from its latest balance sheet (49.5% five years earlier). The financial health section below sets out its other solvency checks.
Who are Neogenomics Inc's competitors?
In our Life Sciences Tools & Services peer group, the companies closest to Neogenomics Inc are Repligen Corp, 10x Genomics, Inc., Azenta, Inc., Veracyte, Inc. and Bio-Techne. The side-by-side comparison below sets their revenue, margins and growth against Neogenomics Inc's.
When is Neogenomics Inc's next earnings date?
Around January 11, 2027, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Neogenomics Inc announces its own schedule.